76 related articles for article (PubMed ID: 10165460)
1. Cost effectiveness scenario analysis for a proposed trial of hormone replacement therapy.
Townsend J; Buxton M
Health Policy; 1997 Mar; 39(3):181-94. PubMed ID: 10165460
[TBL] [Abstract][Full Text] [Related]
2. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
Hettle R; Corbett M; Hinde S; Hodgson R; Jones-Diette J; Woolacott N; Palmer S
Health Technol Assess; 2017 Feb; 21(7):1-204. PubMed ID: 28244858
[TBL] [Abstract][Full Text] [Related]
3. Hormone replacement therapy: a review of the risk versus benefit--Part II.
Oates MB; McGhan WF; Smith MD
Med Interface; 1997 Jan; 10(1):108-14. PubMed ID: 10164503
[TBL] [Abstract][Full Text] [Related]
4. The iterative use of economic evaluation as part of the process of health technology assessment.
Sculpher M; Drummond M; Buxton M
J Health Serv Res Policy; 1997 Jan; 2(1):26-30. PubMed ID: 10180650
[TBL] [Abstract][Full Text] [Related]
5. Expected value of information and decision making in HTA.
Eckermann S; Willan AR
Health Econ; 2007 Feb; 16(2):195-209. PubMed ID: 16981193
[TBL] [Abstract][Full Text] [Related]
6. Assessing the costs and benefits of medical research: the diabetic retinopathy study.
Drummond MF; Davies LM; Ferris FL
Soc Sci Med; 1992 May; 34(9):973-81. PubMed ID: 1631610
[TBL] [Abstract][Full Text] [Related]
7. The INTRABEAM® Photon Radiotherapy System for the adjuvant treatment of early breast cancer: a systematic review and economic evaluation.
Picot J; Copley V; Colquitt JL; Kalita N; Hartwell D; Bryant J
Health Technol Assess; 2015 Aug; 19(69):1-190. PubMed ID: 26323045
[TBL] [Abstract][Full Text] [Related]
8. Searching for a threshold - Not so NICE..
Mooney G; Coast J; Jan S; ; Ryan M; Wiseman V
J Health Serv Res Policy; 2007 Jul; 12(3):190; author reply 190-1. PubMed ID: 17716427
[No Abstract] [Full Text] [Related]
9. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
[TBL] [Abstract][Full Text] [Related]
10. Incorporation of genuine prior information in cost-effectiveness analysis of clinical trial data.
Stevens JW; O'Hagan A
Int J Technol Assess Health Care; 2002; 18(4):782-90. PubMed ID: 12602079
[TBL] [Abstract][Full Text] [Related]
11. The cost of a QALY.
Kirkdale R; Krell J; Brown CO; Tuthill M; Waxman J
QJM; 2010 Sep; 103(9):715-20. PubMed ID: 20519275
[TBL] [Abstract][Full Text] [Related]
12. The use of probabilistic decision models in technology assessment : the case of total hip replacement.
Briggs A; Sculpher M; Dawson J; Fitzpatrick R; Murray D; Malchau H
Appl Health Econ Health Policy; 2004; 3(2):79-89. PubMed ID: 15702945
[TBL] [Abstract][Full Text] [Related]
13. [Evaluation of medical methods--can we rely on cost-benefit-analysis?].
Kristiansen IS; Stavem K; Linnestad K; Pedersen KM
Tidsskr Nor Laegeforen; 2003 Mar; 123(5):657-60. PubMed ID: 12683199
[No Abstract] [Full Text] [Related]
14. Bridging trial and decision: a checklist to frame health technology assessments for resource allocation decisions.
Grutters JP; Seferina SC; Tjan-Heijnen VC; van Kampen RJ; Goettsch WG; Joore MA
Value Health; 2011; 14(5):777-84. PubMed ID: 21839418
[TBL] [Abstract][Full Text] [Related]
15. Unrelated Future Costs and Unrelated Future Benefits: Reflections on NICE Guide to the Methods of Technology Appraisal.
Morton A; Adler AI; Bell D; Briggs A; Brouwer W; Claxton K; Craig N; Fischer A; McGregor P; van Baal P
Health Econ; 2016 Aug; 25(8):933-8. PubMed ID: 27374115
[TBL] [Abstract][Full Text] [Related]
16. Aggregate Distributional Cost-Effectiveness Analysis of Health Technologies.
Love-Koh J; Cookson R; Gutacker N; Patton T; Griffin S
Value Health; 2019 May; 22(5):518-526. PubMed ID: 31104729
[TBL] [Abstract][Full Text] [Related]
17. Value of research and value of development in early assessments of new medical technologies.
Retèl VP; Grutters JP; van Harten WH; Joore MA
Value Health; 2013; 16(5):720-8. PubMed ID: 23947964
[TBL] [Abstract][Full Text] [Related]
18. The costs and benefits of primary total hip replacement. How likely are new prostheses to be cost-effective?
Briggs A; Sculpher M; Britton A; Murray D; Fitzpatrick R
Int J Technol Assess Health Care; 1998; 14(4):743-61. PubMed ID: 9885464
[TBL] [Abstract][Full Text] [Related]
19. Can technology assessment control health spending?
Garber AM
Health Aff (Millwood); 1994; 13(3):115-26. PubMed ID: 7927142
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
